1-(4-bromophenyl)-3-(dimethylamino)-1-pyridin-3-ylpropan-1-ol

We are 1-(4-bromophenyl)-3-(dimethylamino)-1-pyridin-3-ylpropan-1-ol CAS:41910-98-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:1-(4-bromophenyl)-3-(dimethylamino)-1-pyridin-3-ylpropan-1-ol
CAS.NO:41910-98-9
Synonyms:1-(4-bromophenyl)-3-(dimethylamino)-1-pyridin-3-ylpropan-1-ol
α-(4-Bromophenyl)-α-[2-(dimethylamino)ethyl]-3-pyridinemethanol
 
Physical and Chemical Properties:
Density 1.341g/cm3
Boiling Point 464.7ºC at 760 mmHg
Molecular Formula C16H19BrN2O
Molecular Weight 335.23900
Flash Point 234.8ºC
 
Specification:
Appearance:Yellow powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Zimelidine(CAS:56775-88-3).

1-(4-bromophenyl)-3-(dimethylamino)-1-pyridin-3-ylpropan-1-ol


Related News: At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world.4-amino-1-piperidinacarboxilato de etilo CAS:58859-46-4 At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world.(4Z)-4-[[2-methoxy-5-methyl-4-(methylsulfamoyl)phenyl]hydrazinylidene]-3-oxo-N-(2-oxo-1,3-dihydrobenzimidazol-5-yl)naphthalene-2-carboxamide CAS.NO:51920-12-8 This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.80-62-6 This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.

Related Products
Product Name
BOC-ALANINE-1-HYDROXYSUCCINIMIDE ESTER View Details
2,6-Dichloro-4-(trifluoromethyl)phenylhydrazine View Details
N,N”’-1,6-Hexanediylbis(N’-cyanoguanidine) Cas:15894-70-9 View Details
diethyl 2-(thiophen-2-ylmethylidene)propanedioate manufacturer 2-chloro-6-methoxy-1,3-benzothiazole manufacturer ditert-butyl-(2-phenylphenyl)phosphane manufacturer 2,5-Dibromo-3-methylpyridine manufacturer cycloheptylmethanol Cas:4448-75-3 manufacturer